Doctor John Ostrominski
Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)
Member of:
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Event: Heart Failure 2023
Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)
Session: Heart failure with preserved ejection fraction (HFpEF) 3
Duration of heart failure with preserved ejection fraction and treatment with sacubitril/valsartan: insights from the PARAGON-HF trial
Event: Heart Failure 2023
Topic: Epidemiology, Prognosis, Outcome
Session: Chronic heart failure - epidemiology, prognosis, outcome 2
Cardio-renal-metabolic overlap, outcomes, and treatment with dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
Event: Heart Failure 2023
Topic: Comorbidities
Session: Chronic heart failure - comorbidities
